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ABSTRACT 
The objective of the study was to compare the bioavailability of a single oral 
100 mg dose of two brands of phenytoin sodium formulations available in 
the Nepalese market. Formulation B was taken as test drug and compared 
with the innovator brand which was taken as reference standard. A 
randomized, two-way crossover study was done in six healthy adult male 
rabbits. All six rabbits received a single oral 100 mg dose of both the 
formulations with a two-week washout period between the formulations. 
Blood samples for plasma phenytoin levels were collected at 0.25, 1, 2, 4, 6, 
8, 10, 12, 16, 24 hours.  The pharmacokinetic parameters of the two brands 
of phenytoin sodium calculated were area under the concentration versus 
time curve from time zero to 24 hours (AUC 0–24), Area under the Curve 
from time zero to infinity (AUC0–∞), peak plasma concentration (Cmax) and 
time of peak concentration (tmax). Formulation B failed to comply in terms of 
Area under the Curve (AUC), an important pharmacokinetic parameter to 
test bioequivalency, which was tested at significance level 0.05. This showed 
that the test formulation is not bioequivalent with the innovator. Taken 
together, our preliminary findings suggest that further studies in a large 
population is needed before switching phenytoin brands once a patient is 
carefully titrated to a given phenytoin brand. 
INTRODUCTION: More than six decades after its 
introduction, problems of bioavailability and 
bioequivalence continue with phenytoin. Phenytoin 
has three pharmacologic characteristics associated 
with the risk of nonequivalence namely poor water 
solubility, nonlinear kinetics, and a narrow therapeutic 
window 1-2.  
Absorption of phenytoin is highly dependent on the 
formulation of the dosage form. Particle size and 
pharmaceutical additives affect both the rate and 
extent of absorption.  
Phenytoin is highly bound to plasma proteins and its 
metabolism is dose dependent. Its elimination follows 
first-order kinetics (fixed percentage of drug 
metabolized during a per unit time) at the low drug 
concentrations and zero-order kinetics (fixed amount 
of drug metabolized per unit time) at higher drug 
concentrations.  
This change in kinetics reflects the saturation of 
metabolic pathways. Thus, very small increments in 
dosage may result in adverse effects 3. 
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 Bioavailability is defined as the rate and extent 
(amount) of absorption of unchanged drug from its 
dosage form whereas bioequivalence is a relative term 
which denotes that the drug substance in two or more 
identical dosage forms, reaches the systemic 
circulation at the same relative rate and to the same 
relative extent i.e. their plasma concentration-time 
profiles will be identical without significant statistical 
differences 5-6.  
Over the years, issues related to generic drug 
substitution has become a topic of broad discussion 
and hence bioavailability testing of a drug has been a 
topic of research interest. Bioavailability testing is an 
essential prerequisite for generic drug substitution and 
a method of predicting the clinical efficacy of a drug 2.  
Since generic drug substitution is the process of 
dispensing a generic drug product in place of the 
prescribed drug product, it becomes mandatory that 
the substituted product must be a therapeutic 
equivalent to the prescribed product. Generic drug 
products are thus classified as therapeutic equivalents 
and expected to produce the same clinical effect and 
safety profile as the prescribed drug 4. 
On the basis of above facts, the present study was 
undertaken to compare the bioavailability of a single 
oral 100 mg dose of two  brands of phenytoin sodium 
formulations available in the Nepalese  market. 
MATERIALS AND METHODS: 
Chemicals and Reagents: Phenytoin tablets (test 
formulation) with manufactured date june 2008 and 
expiry date may 2010 and phenytoin capsules 
(standard innovator formulation) with manufactured 
date april 2008 and expiry date march 2010 were 
obtained from local retail pharmacy. The reagents: 
water; acetonitrile; methanol used were of HPLC 
grade. 
Phenytoin reference standard (potency: 99.95%) was 
obtained from Zest laboratories private limited, 
Kathmandu, Nepal. Hexobarbital internal standard was 
obtained from clinical pharmacology lab, Institute of 
Medicine, Kathmandu, Nepal. 
Apparatus: All the glass apparatus were from Borosil; 
High Performance Liquid Chromatography was 5 PD- 
10 AVP from Shimadzu, Japan; Analytical balance was 
AW 220 from Shimadzu,Japan; Centrifuge apparatus 
was Labofuge 200 from Kendro laboratory products, 
Germany; Micropipette was Microlit, India; Disposable 
syringe 3ml was from Kana Laboratories, Korea and 
Disposable syringe 1ml was from Terumo, Japan. 
Rabbits: Six adult healthy male rabbits of Angora 
species were used. The mean weight of the rabbits in 
kilograms was 2.523±0.282.The rabbits were divided 
into two groups and named as group 1 and group 2. 
Method: Two ways cross over design was used for 
administration of either of the Phenytoin formulation. 
Group 1 received Standard formulation (Formulation 
A) whereas group 2 received Test formulation 
(Formulation B) during first study period. After a wash 
out period of two weeks group 1 received Formulation 
B and group 2 received Formulation A to complete the 
cross over design.  
Capsule shells were removed from Formulation A and 
the powder were mixed with distilled water to give a 
concentration of 1 mg/ml. Similarly, Formulation B 
were crushed and mixed with distilled water to give a 
concentration of 1mg/ml. After an overnight fasting 
the rabbits were fed either of the formulations of 
Phenytoin 100 mg through disposable syringe 1 ml at a 
dose of 60 mg/kg. The rabbits were then given food 
and drink according to a standard schedule.  
Approximately 2 ml blood samples were withdrawn at 
15 mins, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours from 
marginal ear vein and centrifuged in tubes containing 
EDTA. The plasma was then separated by 
centrifugation (5000 rpm; 5 min) and stored at -10oC 
until analysis were performed using HPLC. After a 
period of two weeks (i.e. washout period) the study 
was repeated in the same manner to complete the 
cross-over design. 
Standard Curve preparation: 50 µL of blank plasma 
and 10 µL of hexobarbital (50 µg/ml) was taken and 
the volume of standard phenytoin solution was varied 
to give final concentration of 10 µg/ml to 60 µg/ml. 60 
µL methanol was added each time to precipitate the 
plasma proteins.  
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After a brief vortex mixing the resulting solution was 
centrifuged for 5 min at 12000 rpm. The supernatant 
were then transferred to another set of clean tubes 
and a 10-20 µL aliquot were injected into the 
chromatographic system.  
The linearity range was then established from 10 µg/ml 
to 60 µg/ml by using linear regression analysis which 
gave the equation of a straight line in the form of: 
y = 0.00351 + 0 .04161 x        (y = a+ bx)-------------------(i) 
Where y is the ratio of standard drug area to that of 
hexobarbital area and x is the standard concentration. 
a is the y intercept and b is the slope of the  straight 
line . The correlation coefficient (r) was found to be 0. 
953. 
Sample analysis: To 50 µL of test plasma sample, 10 µL 
of hexobarbital (as internal standard) (50 µg/ml in 
acetonitrile) and 30 µL of phenytoin standard (50 
µg/ml) and 60 µL of methanol were added. After a 
brief vortex mixing, it was centrifuged for 5 min at 
12,000 rpm. The supernatant were then transferred to 
another set of clean tubes and a 10-20 µL aliquot were 
injected into the chromatographic system. The 
chromatographic conditions consisted of mobile phase 
of acetonitrile and water in the ratio of 25:75 
respectively. Flow rate of 1.5 mL/min was maintained 
through the column (C18).  The peaks were monitored 
at a wavelength of 210 nm at 35oC. 
Pharmacokinetics study: The ratio of drug area to 
hexobarbital area was then fitted in above equation (i) 
to get the values of drug concentration at various time 
intervals. From the concentrations thus obtained Area 
under the plasma concentration time curve from time 
zero to twenty four hours (AUC0–24) was calculated by 
trapezoidal rule where 24 hours was the last time 
point. Area under the plasma concentration − time 
curve from time zero to time infinity (AUC0–∞) was 
calculated as:  
(AUC0–∞) =  AUC0–24 + C24/Ke ------------(ii) 
Where C24 was the last drug concentration measured 
and Ke was the elimination rate constant calculated 
from the slope of the line plotted as log concentration 
versus time. 
Absorption rate constant Ka was calculated by Wagner 
Nelson method. A graph was plotted between log 
percentage Amount remaining to be absorbed (ARA) 
versus time and the slope of the straight line obtained 
times – 2.303 gave the Ka. 
Time of peak concentration (tmax) was then calculated 
by using the following formula: 
Tmax =  2.303 log (Ka / Ke)  
                   Ka – Ke 
Where Ka and Ke are absorption rate constant and 
elimination rate constant respectively.  
Then the value of FXo/ Vd was calculated using 
following formula: 
Ct = FXo/ Vd * Ka/ Ka – Ke (e-Ket – e-Kat) -----------------(iii) 
Where Ct is concentration at certain time t. 
From the values of FXo/ Vd Peak Plasma Concentration 
(Cmax) was then determined by using following formula: 
Cmax = FXo / Vd e- Ke Tmax -------------------------------(iv) 
Validity and Reliability: The method was developed 
after going through original research articles published 
in international peer reviewed, indexed journals. A 
pilot study involving phenytoin formulation (Eptoin 
tablets) on two rabbits were done before the final 
experiment. The study was approved by the Ethical 
Review Board for Research of the Institute of Medicine, 
Tribhuvan University. 
Statistical Analysis of Data: Both univariate and 
bivariate analysis was used for analysis of data. In 
univariate analysis mean, standard deviation, 
confidence interval etc were used. Bivariate analysis 
was done by using student’s t- test. The value set for 
statistical significance was p< 0.05 using two-sided test. 
All the analysis was carried out by using Microsoft 
excel 2003 and STATS version 1.1 1998. 
RESULTS: Area under the Curve from zero to 24 hour. 
Area under the Curve from zero to 24 hour of the two 
formulations were calculated individually and are 
summarized in table 1. 
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TABLE 1: AREA UNDER THE CURVE FROM ZERO TO 24 HOUR OF 
THE TWO FORMULATIONS 
Rabbit 
Formulation A* 
(mcg/mL hr) 
Formulation B* 
(mcg/mL hr) 
R1 258.93 466.32 
R2 546.22 488.78 
R3 250.79 205.62 
R4 481.67 332.26 
R5 380.50 312.07 
R6 287.80 389.37 
Mean ± SD 367.65 ± 124.02 365.74 ± 105.32 
SE 50.62 42.98 
*Different from each other at significance level 0.05, p=0.0224 
Area under the curve from zero to 24 hour of two 
different formulations is shown in table 1. The area 
under the curve of two formulations was significantly 
different from each other at significance level 0.05 (p = 
0.0224). Maximum AUC was shown by R2 for both the 
formulations. 
Area Under the Curve from zero to infinity: Area 
Under the Curve from zero to infinity of the two 
formulations was calculated individually and is 
summarized in table 2. 
TABLE 2: AREA UNDER THE CURVE FROM ZERO TO INFINITY OF 
THE TWO FORMULATIONS 
Rabbit 
Formulation 
A*(mcg/mL hr) 
Formulation B* 
(mcg/mL hr) 
R1 271.81 552.22 
R2 607 664.31 
R3 257.29 222.20 
R4 546.77 349.44 
R5 504.85 338.13 
R6 306.13 404.49 
Mean ± SD 415.64 ± 154.61 421.80 ± 160.12 
SE 63.12 65.37 
*Different from each other at significance level 0.05, p=0.0527 
Area under the curve from zero to infinity of two 
different formulations is shown in table 2. The area 
under the curve of two formulations was significantly 
different from each other at significance level 0.10 (p = 
0.0527). Maximum AUC was shown by R2 for both the 
formulations. 
Time of Peak Concentration (tmax): Time of Peak 
Concentration (tmax) of the two formulations was 
calculated individually and is summarized in table 3. 
TABLE 3: TIME OF  PEAK CONCENTRATION (TMAX) OF THE TWO 
FORMULATIONS 
Rabbit Formulation A* (hr) Formulation B* (hr) 
R1 10.26 10.42 
R2 8.74 7.37 
R3 4.05 7.70 
R4 7.82 4.47 
R5 6.11 11.8 
R6 8.15 6.46 
Mean ± SD 7.52 ± 2.17 8.04 ± 2.67 
SE 0.88 1.09 
*No difference from each other at significance level 0.05, 
p=0.2811 
Time of Peak Concentration (tmax) of two different 
formulations is shown in table 3. The time of Peak 
Concentration (tmax) of two formulations was not 
significantly different from each other at significance 
level 0.05. (p = 0.2811). Maximum time for peak 
concentration was shown by R1 for formulation A 
whereas the time for maximum peak concentration 
was found in R5 for formulation B. 
Peak Plasma Concentration (Cmax): Peak Plasma 
Concentration of the two formulations were calculated 
individually and are summarized in table 4. 
TABLE 4: PEAK PLASMA CONCENTRATION (CMAX) OF THE TWO 
FORMULATIONS 
Rabbit 
Formulation A
#
 
(mcg/mL) 
Formulation B
#
 
(mcg/mL) 
R1 26.05 20.19 
R2 24.20 30.60 
R3 32.13 26.0 
R4 29.28 31.58 
R5 22.56 35.54 
R6 28.34 26.71 
Mean ± SD 27.09 ± 3.51 28.44 ± 5.33 
SE 1.43 2.17 
# No difference from each other at significance level 0.05, 
p=0.3844 
Peak Plasma Concentration (Cmax) of two different 
formulations is shown in table 4. The Peak Plasma 
Concentration (Cmax) of two formulations was not 
significantly different from each other at significance 
level 0.05. (p= 0.3844). Maximum plasma 
concentration was shown by R3 for formulation A 
whereas the maximum concentration was found in R5 
for formulation B. 
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DISCUSSION: Assessment of bioequivalence of local 
product to innovator product is required to exclude 
any clinically important differences in the rate or 
extent at which the active entity of the drugs becomes 
available at the site of action. Two drugs are 
considered to be bioequivalent if they are 
pharmaceutically equivalent and their bioavailability is 
so similar that they are unlikely to produce clinically 
relevant differences in regard to safety and efficacy 7. 
In the present two-way randomized crossover study 
carried out in six healthy adult male rabbits, 
comparison of the bioavailability of one brand of 
phenytoin sodium 100 mg formulation with innovator 
formulation of same strength was done. Both drugs 
were purchased from the retail pharmacy by the 
investigator, and the formulation was administered 
orally in a single 60 mg/kg dose in the fasting state. 
During Pharmacokinetic assessment, the Area Under 
the Curve was significantly different at significance 
level 0.05 while there was no significant difference 
between two formulations in case of Cmax and Tmax at 
significance level 0.05. 
AUC zero to 24 hrs was found to range from 250.79 to 
546.22 µg/ml hr and AUC zero to infinity was in range 
257.29 to 607 µg/ml hr in formulation A whereas AUC 
zero to 24 hrs was found to range from 205.62 to 
488.78 µg/ml hr and AUC zero to infinity was in range 
222.20 to 664.31 µg/ml hr in formulation B. This result 
showed that there was a wide variation in AUC from 
zero to 24 hrs and AUC from zero to infinity between 
rabbits. This variation observed might be due to 
physiological variations between rabbits used in the 
study.  
In a study done by Gogtay et al. it was also seen that 
there is wide variations between AUC of the same 
phenytoin formulation in healthy volunteers 8. 
The bioavailability of drugs is determined by 
gastrointestinal physiological factors and the 
physicochemical property of drugs. The presence of 
food changes the physiological functions of 
gastrointestinal mucosa (e.g., gastric pH, gastric 
emptying, hepatic blood flow) which may lead to 
increase or decrease in the bioavailability of drugs. 
These factors can change pharmacokinetic parameters 
used in assessing bioavailability 9-10. 
The present study in rabbits showed higher peak 
plasma concentration 27.09±3.51 µg/ml  for 
formulation A and 28.44±5.33 µg/ml for formulation B  
than those seen by other researchers. In a similar study 
done by Soma et al.  to determine pharmacokinetics of 
phenytoin in horses, peak plasma concentration 
observed was 11.8±0.68 µg/ml 11. This might be due to 
the fact that phenytoin is highly permeable and there 
might be diluents like binders added in small amounts 
in the formulation. Due to no binding of drug to the 
diluent, a larger amount of drug might have released 
from the formulation. Minain et al. carried similar 
study in rats and Cmax observed was 7.82 µg/ml 12.  
Similarly, time of peak concentration found in the 
present study in rabbits was higher compared to 
similar studies done in the past.  In a study done by 
Gogtay et al., time of peak concentration observed was 
quite lower 8. Time of peak concentration is related to 
the rate of absorption and fasting state of rabbits 
might have resulted in higher time of peak 
concentration. The formulation was administered as a 
solution; it could also have resulted in faster onset 
time with corresponding higher time of peak 
concentration. 
CONCLUSION: The bioequivalence study of two 
formulations of phenytoin sodium 100 mg available in 
Nepalese market showed that the test formulation is 
not bioequivalent with the innovator. The test 
formulation was not significantly different in peak 
plasma concentration and time of peak concentration 
but it was significantly different in terms of Area Under 
the Curve which is the most important parameter in 
evaluating the bioavailability of a drug from its dosage 
form as it represents the extent of absorption. As 
phenytoin is one of the commonly used drugs in the 
treatment of primary and secondary generalized tonic-
clonic epilepsy in Nepal having narrow therapeutic 
index, switching phenytoin brands could have 
significant implications and is not advisable once a 
patient is carefully titrated on one formulation.   
Limitations of Study: The main drawback of this study 
is that it is done only in a small number of animals. 
Though similar environmental conditions and feed is 
provided to rabbits during the study period, there 
might be considerable differences when the drug is 
used in humans. 
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